Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult3. fázis

Efficacy and Safety of Minocycline Add-on in Patients With Neurosyphilis

A legfontosabb adatok

Ki végzi
Beijing Ditan Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
778 fő, tervezett
Kezdés
2026. nov. 15.
Várható befejezés
2028. dec. 22.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Minocycline
  • Minocycline placebo
  • Aqueous crystalline penicillin G
A regiszteradat frissítve
2026. október 29.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18-80 years
  • Diagnosis of neurosyphilis according to the Guidelines for the Diagnosis and Treatment of Syphilis, Gonorrhea and Genital Chlamydia trachomatis Infection (2020)
  • Cognitive impairment (MMSE 10-26) or ischemic stroke-like episodes (time from onset to randomization ≤14 days, NIHSS 1-20)
  • Written informed consent provided by the patient or their legally authorized representative

Ki nem vehet részt

  • Intravenous or intramuscular ceftriaxone for neurosyphilis within 1 month before enrolment (a single intramuscular dose of ceftriaxone for another infection is not exclusionary)
  • Use of tetracycline antibiotics within 1 month before enrolment
  • Systemic immunosuppression meeting any of the following criteria: use of systemic glucocorticoids (oral or intravenous) within 3 months before enrolment (prednisone-equivalent dose >10 mg/day for >2 weeks); current use of immunosuppressants (including but not limited to methotrexate, azathioprine, ciclosporin, mycophenolate mofetil, TNF-α inhibitors, or JAK inhibitors); or discontinuation of immunosuppressants within <4 weeks or <5 half-lives (whichever is longer)
  • Current participation in another investigational drug or device trial
  • Allergy or resistance to penicillin or tetracycline antibiotics (including minocycline)
  • History of psychiatric disorders (e.g., schizophrenia or depression)
  • Cognitive impairment from other causes (e.g., Alzheimer's disease, frontotemporal dementia, thyroid dysfunction, folate/vitamin B12 deficiency, or alcohol use disorder)
  • Ischaemic stroke clearly attributable to other aetiologies
  • Active co-infection with central nervous system opportunistic pathogens (e.g., tuberculous meningitis, cryptococcal meningitis, toxoplasmic encephalitis, or cytomegalovirus encephalitis)
  • Other central nervous system or systemic diseases causing abnormal cerebrospinal fluid parameters (including but not limited to autoimmune encephalitis, multiple sclerosis, central nervous system tumours, systemic lupus erythematosus, antiphospholipid syndrome, sarcoidosis, or systemic vasculitis)
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation or unable to comply with the protocol
  • HIV infection meeting any of the following criteria: screening CD4+ T-cell count <200 cells/μL; or virological failure, defined as receiving antiretroviral therapy for ≥6 months with two consecutive plasma HIV RNA levels >200 copies/mL (measured 2-4 weeks apart)
  • Severe renal impairment (serum creatinine >3.0 mg/dL [265.2 μmol/L], glomerular filtration rate <30 mL/min/1.73 m², or on dialysis) or severe hepatic impairment (ALT or AST >3 × upper limit of normal)
  • Pre-morbid modified Rankin Scale (mRS) score >2
  • Severe underlying comorbidities with an expected life expectancy of <1 year
  • Pregnancy or lactation; or women of childbearing potential with a negative pregnancy test who decline to use effective contraception

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Study Objective: Neurosyphilis remains a major clinical challenge: despite standard first-line therapy with intravenous penicillin G, as recommended by international and Chinese guidelines, approximately 30% of patients have residual neurological impairment. Minocycline, a tetracycline antibiotic, has both anti-Treponema pallidum activity and independent anti-inflammatory and neuroprotective effects. We therefore designed a prospective, multicenter, randomized, double-blind, placebo-controlled trial to evaluate whether the addition of minocycline to penicillin, as compared with penicillin monotherapy, improves the 6-month rate of favorable neurological outcomes in patients with neurosyphilis. This trial will provide evidence-based evidence for the treatment of neurosyphilis. Inclusion Criteria: 1)Age 18-80 years; 2)Diagnosis of neurosyphilis according to the Guidelines for the Diagnosis and Treatment of Syphilis, Gonorrhea and Genital Chlamydia trachomatis Infection (2020); 3)Cognitive impairment (MMSE score 10-26) or ischemic stroke-like episodes (time from onset to randomization ≤14 days, NIHSS score 1-20); 4)Written informed consent provided by the patient or their legally authorized representative. Intervention: Participants will be randomly assigned ( by chance ) to one of two groups. Group 1 will receive standard intravenous penicillin therapy plus oral minocycline for 28 days. Group 2 will receive standard intravenous penicillin therapy plus oral placebo for 28 days. All participants will receive standard penicillin treatment. Participants and their doctors will not know which group they are in. Follow-up: Participants will be followed for up to 12 months, with five follow-up visits: baseline (before treatment initiation), end of intravenous penicillin treatment (Day 12 ± 2 days), end of minocycline treatment (Day 28 + 2 days), 6 months post-treatment (Month 6 ± 7 days), and 12 months post-treatment (Month 12 ± 7 days). Assessments will include standardized neurological function scales for favorable neurological outcomes, cognitive function, neurological deficits, and activities of daily living; cerebrospinal fluid and serum efficacy marker testing; and brain MRI.

A teljes eredeti leírásKevesebb

Potential Benefits and Risks: Participants may or may not benefit from participating in this study. All participants will receive standard treatment for neurosyphilis. The main risks are complications that may occur during study procedures (such as lumbar puncture, or allergic reactions to penicillin) and possible side effects of minocycline, including dizziness, vestibular side effects, nausea, or skin sensitivity to sunlight. The study team will closely monitor participants for any adverse reactions. Importance of This Study: If minocycline does help improve neurological outcomes, it could become a new treatment option for patients with neurosyphilis, thereby helping to reduce the occurrence of neurological sequelae. The implementation of this study will provide evidence-based evidence for the treatment of neurosyphilis.

A vizsgálat 2 csoportja

  • Penicillin plus MinocyclineA vizsgált kezelés

    Participants will receive standard intravenous aqueous crystalline penicillin G (18-24 million units/day for 10-14 days) plus oral minocycline (200 mg loading dose on Day 1, followed by 100 mg every 12 hours) for 28 days.

    Kezelés: Minocycline és Aqueous crystalline penicillin G

  • Penicillin plus PlaceboPlacebo, összehasonlításként

    Participants will receive standard intravenous aqueous crystalline penicillin G (18-24 million units/day for 10-14 days) plus oral matching minocycline placebo (200 mg loading dose on Day 1, followed by 100 mg every 12 hours) for 28 days.

    Kezelés: Minocycline placebo és Aqueous crystalline penicillin G

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy and Safety of Minocycline Add-on in Patients With Neurosyphilis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (MIN-ADD)
Kérdések a feltételekről
Forrás: NCT07904533: ki vehet részt
A regiszteradat frissítve
2026. október 29.